Abstract Treatment of primary intraocular uveal melanoma has developed considerably, its
driver genes are largely unraveled, and the ways to assess its risk for metastases are very …

Simple Summary The development of uveal melanoma is a multifactorial and multi-step
process, in which specific and recurrent mutations arise early. Among the recurrently …

Background Increasing evidence suggests a correlation between glycosylation and the
onset of cancer. However, the clinical relevance of glycosylation-related genes (GRGs) in …

The use of biomarkers in medicine has become essential in clinical practice in order to help
with diagnosis, prognostication and prediction of treatment response. Since Alexander …

Simple Summary Survival after diagnosis of metastatic uveal melanoma has not significantly
improved over decades, most patients die within a year from diagnosis. Uveal melanoma is …

Uveal melanoma (UM) represents the most common intraocular malignancy in adults and
accounts for about 5% of all melanomas. Primary disease can be effectively controlled by …

Purpose: Uveal melanoma is the most common eye cancer in adults. Approximately 50% of
patients with uveal melanoma develop metastatic uveal melanoma (mUM) in the liver, even …

Tumor-specific neoepitopes are promising targets in cancer immunotherapy. However, the
identification of functional tumor-specific neoepitopes remains challenging. In addition to the …

Simple Summary Uveal melanoma is the most common primary intraocular malignancy in
adults. Unfortunately, metastasis develops in up to 50% of cases and outcomes are poor for …

The FDA granted orphan drug designation to darovasertib, a first-in-class oral, small
molecular inhibitor of protein kinase C (PKC), for the treatment of uveal melanoma, on 2 May …